Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases Reply

被引：0
|
作者：
Ben-Horin, Shomron [1 ,2 ]
Ungar, Bella [1 ,2 ]
机构：
[1] Tel Aviv Univ, Sheba Med Ctr Tel Hashomer, Dept Gastroenterol, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 14卷 / 10期
关键词：
D O I：
10.1016/j.cgh.2016.06.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1509 / 1510
页数：3
相关论文
共 50 条
  • [1] Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
    Ordas, Ingrid
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (10) : 1079 - 1087
  • [2] Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases
    Yarur, Andres J.
    Rubin, David T.
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (07) : 1709 - 1718
  • [3] Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
    Siddharth Singh
    Herbert C. Heien
    Lindsey Sangaralingham
    Nilay D. Shah
    William J. Sandborn
    Digestive Diseases and Sciences, 2022, 67 : 2510 - 2516
  • [4] Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert C.
    Sangaralingham, Lindsey
    Shah, Nilay D.
    Sandborn, William J.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2510 - 2516
  • [5] Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
    John T Chang
    Gary R Lichtenstein
    Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3 : 220 - 228
  • [6] Drug insight:: Antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
    Chang, JT
    Lichtenstein, GR
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (04): : 220 - 228
  • [7] Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert
    Herrin, Jeph
    Dulai, Parambir S.
    Sangaralingham, Lindsey
    Shah, Nilay
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S444 - S445
  • [8] Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease Reply
    Bouguen, Guillaume
    Brunet, Tanguy
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 855 - 856
  • [9] Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring
    Pais, Isabel Pinto
    Espinheira, Maria C.
    Trindade, Eunice
    Dias, Jorge Amil
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (01): : 12 - 18
  • [10] Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease
    Andersen, Nynne Nyboe
    Pasternak, Bjorn
    Basit, Saima
    Andersson, Mikael
    Svanstrom, Henrik
    Caspersen, Sarah
    Munkholm, Pia
    Hviid, Anders
    Jess, Tine
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23): : 2406 - 2413
12345